Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia

Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04348448

Enrollment

100

Registered

2020-04-16

Start date

2020-02-01

Completion date

2020-09-01

Last updated

2023-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.

Interventions

DRUGCanakinumab 150 MG/ML [Ilaris]

COVID-19

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* patients with COVID 19 who have received or are candidates to receive treatment with canakinumab subcutaneously * Age\> 18 years * Pneumonia diagnosed with Chest X-ray / or Chest CT

Exclusion criteria

* Patients with Covid19-related pathology in the context of another cause of major admission (trauma, surgery)

Design outcomes

Primary

Measure	Time frame	Description
intensive care treatment	9 months	percentage of patients treated with canakinumab sc who do not require intensive care treatment during hospitalization for COVID-19

Secondary

Measure	Time frame	Description
ICU stay times	9 months	ICU stay times
% died after 1 month after treatment	9 months	percentage of patients who died 1 month after treatment
hospitalization	9 months	time of hospitalization
adverse event	9 months	number of adverse event

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026